This contract program supported development of HIV-1 hyper-immune globulin (HIVIG) from an infected person's plasma, with the expectation that it could prove useful for prophylaxis after HIV exposure (needle stick, sexual contact, etc.).
The program supported one contract and ended in 1990.
The immunoglobulin was tested in chimpanzees, where it proved effective in preventing infection after viral exposure.
This successful development of HIVIG eventually led to the ongoing trial of HIVIG in pregnant women.